Header Logo

Connection

Theodore Pincus to Clinical Trials as Topic

Back to Details
This is a "connection" page, showing publications Theodore Pincus has written about Clinical Trials as Topic.
Theodore Pincus
Connection Strength
3.534
Clinical Trials as Topic
  1. Limitations of clinical trials in chronic diseases: is the efficacy of methotrexate (MTX) underestimated in polyarticular psoriatic arthritis on the basis of limitations of clinical trials more than on limitations of MTX, as was seen in rheumatoid arthritis? Clin Exp Rheumatol. 2015 Sep-Oct; 33(5 Suppl 93):S82-93.
    View in: PubMed
    Score: 0.475
  2. Clinical trials documenting the efficacy of low-dose glucocorticoids in rheumatoid arthritis. Neuroimmunomodulation. 2015; 22(1-2):46-50.
    View in: PubMed
    Score: 0.441
  3. Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target. Bull Hosp Jt Dis (2013). 2013; 71 Suppl 1:S33-40.
    View in: PubMed
    Score: 0.392
  4. Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials. J Rheumatol. 2006 Dec; 33(12):2372-5.
    View in: PubMed
    Score: 0.257
  5. A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS/PAS-II). J Rheumatol. 2005 Dec; 32(12):2410-5.
    View in: PubMed
    Score: 0.240
  6. Clinical trials in rheumatic diseases: designs and limitations. Rheum Dis Clin North Am. 2004 Nov; 30(4):701-24, v-vi.
    View in: PubMed
    Score: 0.223
  7. Quantitative measures and indices to assess rheumatoid arthritis in clinical trials and clinical care. Rheum Dis Clin North Am. 2004 Nov; 30(4):725-51, vi.
    View in: PubMed
    Score: 0.223
  8. Add-on or step-up trials in rheumatoid arthritis: comment on the article by Boers. Arthritis Rheum. 2004 Apr; 50(4):1351; author reply 1351-2.
    View in: PubMed
    Score: 0.214
  9. Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care. Best Pract Res Clin Rheumatol. 2003 Oct; 17(5):753-81.
    View in: PubMed
    Score: 0.206
  10. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum. 2003 Feb; 48(2):313-8.
    View in: PubMed
    Score: 0.197
  11. Proposed severity and response criteria for Routine Assessment of Patient Index Data (RAPID3): results for categories of disease activity and response criteria in abatacept clinical trials. J Rheumatol. 2011 Dec; 38(12):2565-71.
    View in: PubMed
    Score: 0.091
  12. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011 Mar; 70(3):404-13.
    View in: PubMed
    Score: 0.086
  13. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011 Mar; 63(3):573-86.
    View in: PubMed
    Score: 0.086
  14. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum Dis Clin North Am. 2009 Nov; 35(4):773-8, viii.
    View in: PubMed
    Score: 0.079
  15. Are excellent systematic reviews of clinical trials useful for patient care? Nat Clin Pract Rheumatol. 2008 Jun; 4(6):294-5.
    View in: PubMed
    Score: 0.071
  16. Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2008; 66(3):216-23.
    View in: PubMed
    Score: 0.069
  17. Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol. 2008 Feb; 35(2):201-5.
    View in: PubMed
    Score: 0.069
  18. An index of patient reported outcomes (PRO-Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol. 2006 Nov; 33(11):2146-52.
    View in: PubMed
    Score: 0.064
  19. Guidelines for monitoring of methotrexate therapy: "evidence-based medicine" outside of clinical trials. Arthritis Rheum. 2003 Oct; 48(10):2706-9.
    View in: PubMed
    Score: 0.052
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.